Delivery Order SPE2DB25D3108-SPE2DB25FPDNC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of ProQuad vials valued at $5,426.92, with an ultimate completion date of August 14, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award was made through open competition with no...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of ProQuad vials valued at $13,234.64 with a completion date of August 11, 2025. This non-competitive delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The performance location is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product, with a completion date of August 21, 2025. This competitive award (no set-aside used) was issued under a firm fixed-price structure and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,670.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 15, 2025. This is a non-set-aside, competitively awarded contract executed on July 25, 2025, with performance at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of ProQuad vials, a combination vaccine product. This firm fixed price delivery order, valued at $6,405.01, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is non-set-aside and was competitively awarded, with performance to be completed by August 20, 2025, at AmerisourceBergen's Corporate...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order for ProQuad vials valued at $6,683.60 by the Defense Logistics Agency (DLA). The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $3,341.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on July 21, 2025, with an ultimate completion date of August 11, 2025. This competitive award, issued without set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. ProQuad is a combination vaccine protecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.44, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $8,354.50 under a firm fixed-price contract. The award was made on July 25, 2025, with an ultimate completion date of August 15, 2025. This is a non-set-aside, competitively awarded delivery order, with performance to take place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. ProQuad is a combination vaccine used for immunization against measles,...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDNCDelivery Order
The Defense Logistics Agency awarded a $5,480.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. ProQuad is a combination vaccine used for immunization against measles, mumps, rubella, and varicella, representing part of the company's extensive portfolio of pharmaceutical and medical supply deliveries to federal agencies. This delivery order exemplifies AmerisourceBergen's role as a critical vendor within DLA's pharmaceutical supply chain. The company maintains a $999.999 billion IDC with DLA Troop Support Medical (contract SPE2DX) extending through December 2026, which serves as the foundational vehicle enabling such delivery orders for medical commodities worldwide. The non-set-aside competitive award demonstrates AmerisourceBergen's sustained capability to fulfill federal medical supply requirements and aligns with the Defense Logistics Agency's strategy to maintain reliable vaccine and pharmaceutical distribution channels supporting Defense Health Agency operations and broader military healthcare missions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 7/31/25 |